DRI Healthcare Trust
TSX:DHT-U.TO · Toronto Stock Exchange
-$0.23 today
Vol 0.00M · Avg 0.00M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
-11.7%
avg 105.0%
ROIC
6.4%
avg 105.6%
ROA
-5.5%
avg 2.0%
Analysis
ROIC is currently the strongest return metric at 6.4% versus its period average of 105.6%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Babak Farahmand | Executive Vice President of Asset Operations & Analytics - DRI Capital Inc. | — | — | — | — | — |
Emmanuel Coeytaux | Executive Vice President of Strategy | — | — | — | — | — |
Lee Schechter | Senior Vice President of Research & Investments | — | — | — | — | — |
Navin Cyriac Jacob | Executive Vice President, Head of Investments & Research - DRI Capital Inc. | — | — | — | — | — |
Zaheed Mawani | Chief Financial Officer | — | — | — | — | — |
Insider Trading
SEC Form 4 transactions — last 12 months
No insider transactions in the last 12 months.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A1 analysts |
| Revenue | N/A | N/A | +23.6% | +9.0% (6yr)6 analysts |
| Net Income | N/A | N/A | N/A | N/A6 analysts |
| EBIT | N/A | N/A | +94.6% | N/A6 analysts |
Analysis
Recent growth has been strongest in EBIT at +94.6% over three years. Forward estimates point to Revenue at +9.0% (6yr), giving you a quick check on whether expectations are accelerating or cooling.
Competitors
Peer companies in the same sector
Dexterra Group Inc.
TSX:DXT.TO
$809.53M
DRI Healthcare Trust
DHT-UN.TO
$672.75M
Aquestive Therapeutics, Inc.
NASDAQ:AQST
$462.27M
Cipher Pharmaceuticals Inc.
TSX:CPH.TO
$408.04M
Dream Residential Real Estate Investment Trust
DRR-U.TO
$211.15M
OrganiGram Holdings Inc.
TSX:OGI.TO
$189.69M
HLS Therapeutics Inc.
TSX:HLS.TO
$131.35M
European Residential Real Estate Investment Trust
ERE-UN.TO
$110.80M
Who manages DHT-U.TO?
DRI Healthcare Trust (DHT-U.TO) lists 5 active executives. The top listed executive is Babak Farahmand, Executive Vice President of Asset Operations & Analytics - DRI Capital Inc..
Explore More
Continue the stock analysis
Jump to another research area for this company.